Skip to main content
Premium Trial:

Request an Annual Quote

Spectrumedix Dissolves, Transgenomic to Maintain Service, Supply Stream

NEW YORK (GenomeWeb News) — Spectrumedix, a maker of high-throughput capillary-electrophoresis tools, closed its doors last month, according to Transgenomic, a Spectrumedix distributor.
To make up for the resulting supply problems created by the dissolution, which occurred March 9, Transgenomic said it has purchased “certain assets” from the company’s court-appointed receiver along with a license to a gel patent it needs to make consumables for the Spectrumedix systems.
Transgenomic will continue to offer service and support to Spectrumedix customers in the US and elsewhere. The company said Spectrumedix-made tools are used in comparative genome scanning, SNP genotyping, heterozygote identification, fragment sizing, PCR quality testing, and custom assay development.
Transgenomic CEO Craig Tuttle said the company has been “concerned” about the supply of consumables and spare parts to its customers in Europe, and said this series of moves “clarifies the situation” for former Spectrumedix customers as well.
Financial terms of the deal were not released.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more